March 22, 2018
Nativis to Present at 17th Annual Needham & Co. Healthcare Conference
Updates to include partnerships, clinical progress and plans for 2018
SEATTLE – March 22, 2018 –Nativis, Inc., a clinical stage therapeutic device company developing non-sterile, non-thermal, non-invasive treatments for cancers and other serious diseases, today announced that it will be featured as a presenting company at the Needham & Company 17th Annual Healthcare Conference being held on March 27–28, 2018, at The Westin NY Grand Central Hotel.
Chris E. Rivera, Nativis President and Chief Executive Officer, will provide an overview of the company’s progress in 2017, new developments in the first quarter of 2018, and a look forward during a live presentation. Rivera will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
Institutional investors who would like to attend the company’s presentation, can register here for the conference. Once registration is confirmed, investors can log into the conference website to request a one-on-one meeting with Nativis.
Details for Rivera’s presentation are as follows:
Date: Monday, March 28, 2018
Time: 3:00 p.m. EDT
Last month, Nativis announced it has received notice from the Food & Drug Administration (FDA) that the Nativis Voyager® Pediatric system has been granted a Humanitarian Use Designation (HUD). This new device is designed to treat medulloblastoma, a rare, high-grade glioma in children.
Rivera made the announcement stating, “This is an important step for our company and a great start for 2018. A subsequent FDA approval for a Humanitarian Device Exemption will enable us to begin commercialization of the Voyager Pediatric system in the U.S. to treat medulloblastoma as early as fourth quarter of 2018. More importantly, it will provide a potential treatment for children with brain cancer, where there is not currently a viable therapy on the market.”
In 2017, Nativis announced it had entered into an exclusive licensing agreement for the development and commercialization of Nativis’ proprietary ultra-low radio frequency energy (ulRFE®) technology for the potential treatment of glioblastoma multiforme (GBM) in the Japanese market, with Teijin Limited, a comprehensive Japanese company expanding businesses in high-performance materials, pharmaceuticals, home healthcare, product converting and information technology.
About Nativis, Inc.
Founded in 2002 and headquartered in Seattle, WA, Nativis is a clinical-stage therapeutic device company. Nativis has invented and patented a groundbreaking technology that utilizes precisely targeted, ulRFE to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use, non-invasive, portable device called Nativis Voyager®. The company’s goal is to transform disease treatment on a global scale with ulRFE, which can potentially be applied to a wide range of medical conditions as well as to veterinary medicine and non-medical applications (such as agriculture and bio-fuels). Nativis’ initial focus is on the treatment of patients with brain cancer, who are not well served by conventional standard of care therapies, which often result in poor outcomes and devastating side effects. Additional pre-clinical work is exploring new applications in oncology. The Nativis Voyager ulRFE system for adults with GBM is an investigational medical device, limited by United States law to investigational use only.
Investor and Media Relations Contact: